(Q36924692)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

title

Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

0 references

Patrick A Flume

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Brian P O'Sullivan

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Karen A Robinson

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Peter J Mogayzel

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Donna Beth Willey-Courand

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Janet Bujan

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Jonathan Finder

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Lynne Quittell

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Randall Rosenblatt

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Robert L Vender

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Leslie Hazle

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Kathy Sabadosa

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Bruce Marshall

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Cystic Fibrosis Foundation, Pulmonary Therapies Committee

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

language of work or name

English

0 references

publication date

29 August 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Respiratory and Critical Care Medicine

4 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

volume

176

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

page(s)

957-969

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761616%20AND%20SRC:MED&resulttype=core&format=json

Consensus conference: practical applications of Pulmozyme. September 22, 1993.

4 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Current methods of the US Preventive Services Task Force: a review of the process

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Efficacy of aerosolized tobramycin in patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Dornase alfa as postoperative therapy in cystic fibrosis sinonasal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Dornase alpha and exhaled NO in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Dornase alfa reduces air trapping in children with mild cystic fibrosis lung disease: a quantitative analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Use of computerized tomography and chest x-rays in evaluating efficacy of aerosolized recombinant human DNase in cystic fibrosis patients younger than age 5 years: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Mucus clearance and lung function in cystic fibrosis with hypertonic saline

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Interleukin-1 alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Prednisolone in the treatment of airflow obstruction in adults with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Effect of high-dose ibuprofen in patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

A pilot study of zafirlukast as an anti-inflammatory agent in the treatment of adults with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

A double-blind, randomized study of sodium cromoglycate versus placebo in patients with cystic fibrosis and bronchial hyperreactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Erythromycin and diffuse panbronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

A placebo-controlled trial of cephalexin therapy in the ambulatory management of patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Pulmonary function in infants with cystic fibrosis: the effect of antibiotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Effectiveness and tolerability of high-dose salmeterol in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Effects of salmeterol on arterial oxyhemoglobin saturations in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

RhDNase before airway clearance therapy improves airway patency in children with CF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Microbiological and immunologic considerations with aerosolized drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Pharmacokinetics of inhaled drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Safety of repeated intermittent courses of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Multicenter, open-label study of recombinant human DNase in cystic fibrosis patients with moderate lung disease. DNase International Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Effect of rhDNase on lung function and quality of life in adult cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

DNase in stable cystic fibrosis infants: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Controlled Trial of Inhaled Budesonide in Patients with Cystic Fibrosis and Chronic BronchopulmonaryPseudomonas aeruginosaInfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Multicenter Randomized Controlled Trial of Withdrawal of Inhaled Corticosteroids in Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC

Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200705-664OC